134017-78-0

134017-78-0 structure
134017-78-0 structure
  • Name: U89232
  • Chemical Name: 1-cyano-2-[(3R,4S)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-(2-methylbutan-2-yl)guanidine
  • CAS Number: 134017-78-0
  • Molecular Formula: C19H25N5O2
  • Molecular Weight: 355.43400
  • Catalog: Signaling Pathways Membrane Transporter/Ion Channel Potassium Channel
  • Create Date: 2016-03-30 03:48:15
  • Modify Date: 2024-03-26 20:16:48
  • U-89232 appears to be a cardioselective KATP channel opener.

Name 1-cyano-2-[(3R,4S)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-(2-methylbutan-2-yl)guanidine
Synonyms Guanidine,N-cyano-N'-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N''-(1,1-dimethylpropyl)
trans-N-Cyano-N'-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N''-(1,1-dimethylpropyl)guanidine
U89232
Description U-89232 appears to be a cardioselective KATP channel opener.
Related Catalog
Target

KATP channel[1]

In Vivo U-89232, a derivative of the ATP-sensitive potassium (KATP) channel opener Cromakalim. Experiments are performed in open-chest pigs subjected to a 60-min occlusion of the left anterior descending coronary artery (LADCA) and to 2 h of reperfusion. Four groups of animals are studied (n=6 each). Animals receive either U-89232, 3 mg/kg i.v. over a 15-min period (U), or Glibenclamide, a selective KATP channel blocker, 1 mg/kg i.v. over a 15-min period (GLI) before the LADCA occlusion. In the GLI+U group, first Glibenclamide (1 mg/kg/15 min) and then U-89232 (3 mg/kg/15 min) are infused before the 60 min of ischemia. Saline-treated animals serve as controls (CON). Hemodynamic parameters are continuously monitored. Regional contractile wall function is quantified with ultrasonic crystals aligned to measure wall thickening. At the end of the protocol, infarct size (IS, as percentage of risk region) is determined by incubating the myocardium with p-nitrobluetetrazolium. With comparable myocardium at risk, infusion of U-89232 before 60 min of LADCA occlusion significantly reduces infarct size (IS, 18.5±3.7%; p<0.001 vs. 63.2±3.3% for the controls), whereas glibenclamide has no effect on infarct size (IS, 69.5±4.4%). The administration of glibenclamide before U-89232 infusion blocks the infarct size-reducing effect of U-89232. At least in a pig model, U-89232 appears to be a cardioselective KATP channel opener, because in the absence of hemodynamic alterations, it exhibits a profound cardioprotective effect, which is fully reversible by blocking KATP channels[1].
References

[1]. Rohmann S, et al. In swine myocardium, the infarct size reduction induced by U-89232 is glibenclamide sensitive: evidence that U-89232 is a cardioselective opener of ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 1997 Jan;29(1):69-74.

Density 1.18g/cm3
Boiling Point 492.2ºC at 760 mmHg
Molecular Formula C19H25N5O2
Molecular Weight 355.43400
Flash Point 251.5ºC
Exact Mass 355.20100
PSA 113.46000
LogP 3.11796
Vapour Pressure 1.67E-10mmHg at 25°C
Index of Refraction 1.585
Storage condition 2-8℃
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.